Skip to main content
Equibles

Matthew W. Rosinack

Iovance Biotherapeutics, Inc. (IOVA)

Chief Accounting Officer

Iovance Biotherapeutics, Inc. (IOVA)

Equibles does not estimate personal net worth.

Get an email with a short summary when Iovance Biotherapeutics, Inc. publishes a filing, an earnings call transcript or a press release.

Get IOVA alerts

About Matthew W. Rosinack

Matthew W. Rosinack is recorded as Chief Accounting Officer at Iovance Biotherapeutics, Inc. (IOVA) since June 30, 2025. Iovance Biotherapeutics, Inc. reported in an 8-K filed July 3, 2025 that Matthew W. Rosinack was appointed interim Principal Financial Officer and Principal Accounting Officer, effective June 30, 2025. Iovance Biotherapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Iovance Biotherapeutics, Inc. includes Frederick G. Vogt, Ph.D. (CEO), Frederick Vogt (CEO and General Counsel), Corleen Roche (CFO) and 7 others.

“Effective as of June 30, 2025, Matthew W. Rosinack, the Company's Senior Vice President, Finance, was appointed as the Company's interim Principal Financial Officer and Principal Accounting Officer.”
Iovance Biotherapeutics, Inc. Form 8-K, filed July 3, 2025 · Read the filing

Affiliation history

Company network

Leadership on record at Iovance Biotherapeutics, Inc.

Recent activity